Annovis Bio
Stage
IPO | IPOTotal Raised
$11.88MDate of IPO
1/29/2020Market Cap
0.07BAbout Annovis Bio
Annovis Bio (NYSE: ANVS) is a clinical-stage, drug platform company addressing chronic and acute neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). Annovis' approach is to develop drugs that normalize the transport of information within and between nerve cells, called axonal transport. Its drug, ANVS-401, restores axonal transport and homeostasis in the brain by inhibiting the synthesis of neurotoxic proteins. Annovis has an ongoing Phase 2a proof-of-concept study in mild to moderate AD patients and a ready program to conduct a second Phase 2a study in PD patients.
Annovis Bio Headquarter Location
1055 Westlakes Drive Suite 300
Berwyn, Pennsylvania, 19312,
United States
610-727-3913
Expert Collections containing Annovis Bio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Annovis Bio is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Annovis Bio Patents
Annovis Bio has filed 7 patents.
The 3 most popular patent topics include:
- Rare diseases
- Neurological disorders
- Proteins
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/8/2019 | 8/24/2021 | Acetylcholinesterase inhibitors, Rare diseases, Psychiatric diagnosis, Monoclonal antibodies, Organophosphate insecticides | Grant |
Application Date | 7/8/2019 |
|---|---|
Grant Date | 8/24/2021 |
Title | |
Related Topics | Acetylcholinesterase inhibitors, Rare diseases, Psychiatric diagnosis, Monoclonal antibodies, Organophosphate insecticides |
Status | Grant |
Latest Annovis Bio News
May 4, 2022
Annovis Bio press release (NYSE: ANVS ): Q1 Net Loss of $5.9M Cash, cash equivalents, and marketable securities were $42.7 million as of March 31, 2022. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Annovis Bio Web Traffic
Annovis Bio Rank
Where is Annovis Bio's headquarters?
Annovis Bio's headquarters is located at 1055 Westlakes Drive, Berwyn.
What is Annovis Bio's latest funding round?
Annovis Bio's latest funding round is IPO.
How much did Annovis Bio raise?
Annovis Bio raised a total of $11.88M.
Who are the investors of Annovis Bio?
Investors of Annovis Bio include Metalmark Capital, Robin Hood Ventures, Delaware Crossing Investment Group, Michael Hoffman, Keiretsu Forum and 4 more.
Who are Annovis Bio's competitors?
Competitors of Annovis Bio include Intarcia Therapeutics, Synapsin Pharmaceuticals, CoMentis, Hyperion Therapeutics, Neuronascent and 16 more.
You May Also Like
Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.
Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.
Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.
Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.